[Transfer of interleukin 2-activated lymphocytes]

Area of Science:

• Immunology
• Cellular Therapy
• Cancer Research

Context:

• Adoptive immunotherapy utilizes potent effector cells, such as interleukin-2-activated killer (LAK) cells, for treating advanced cancers.
• Understanding LAK cell characteristics and optimizing their application is crucial for enhancing therapeutic outcomes.
• Previous studies have explored LAK cell therapy, but efficient administration methods require further investigation.

Purpose:

• To characterize LAK cells and evaluate their behavior against metabolic inhibitors.
• To assess the efficacy and safety of LAK cell transfer through simulation studies in mice.
• To investigate the therapeutic potential of localized versus systemic LAK cell administration in advanced cancer patients.

Summary:

• LAK cells, primarily found in low-density fractions of human peripheral blood lymphocytes, exhibit distinct metabolic profiles compared to Natural Killer (NK) cells.
• FACS sorting using CD16 and CD3 markers identified LAK activity, a finding previously obscured by LAK cell sensitivity to sodium azide.
• Simulation studies in mice showed no adverse effects and significant efficacy against lung and abdominal tumors. A human pilot study involving 25 advanced carcinoma patients indicated superior therapeutic outcomes with local LAK cell transfer over systemic administration.

Impact:

• This research provides fundamental insights into LAK cell biology and their distinct properties.
• The findings highlight the potential of localized LAK cell therapy as a more effective treatment strategy for advanced cancers.
• Optimizing LAK cell application through local transfer could improve patient outcomes in adoptive immunotherapy.